People with obesity and heart failure who take tirzepatide might have a lower chance of dying from heart problems and feel better with fewer heart failure symptoms.

1

Pro

0

Against

Evidence from Studies

Supporting (1)

1

Community contributions welcome

1

GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease.

Narrative Review

Human

2025 Jul

The study looked at tirzepatide in people with obesity and heart failure, and found it helped reduce heart-related deaths and eased heart failure symptoms, just like the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease.

Score: 1

DOI: 10.1016/j.medcli.2025.106951

Similar Assertions

People with obesity or type 2 diabetes who take tirzepatide are much more likely to lose a meaningful amount of weight—like 5%, 10%, or even 15% of their body weight—compared to those who don’t, and the more they take, the better the results seem to be.

50

0

75%

People with obesity or type 2 diabetes who took a drug called tirzepatide lost a lot of weight—more when they took higher doses—and the effect lasted up to about three years.

50

0

72%